Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are male or female patients, 13 to 17 years of age~* Patients must have a diagnosis of schizophrenia per DSM-IV-TR.~* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment.~* Both the patient and the patient's parent/authorized legal representative must understand the nature of the study and must sign a document granting consent.~* Patients must be capable of swallowing study medication whole (without crushing, dissolving, etc.)~Exclusion Criteria:~* Female patients who are either pregnant or nursing.~* Patients with acute or unstable medical conditions.~* Patients who have been judged clinically to be at serious suicidal risks.~* Patients who have previously not responded to an adequate dose and/or duration of olanzapine treatment.~* Patients who currently have delusional disorder, psychotic disorder NOS, schizophreniform, schizoaffective disorder, bipolar disorder, attention deficit/hyperactivity disorder or major depressive disorder.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).